Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTP4A3 | O75365 | 1/20 | 0.60 |
| ▸ | NAT1 | P18440 | 2/20 | 0.54 |
| ▸ | GSK3A | P49840 | 2/20 | 0.54 |
| ▸ | PIM1 | P11309 | 3/20 | 0.50 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.50 |
| ▸ | TTR | P02766 | 2/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13846584 | 1.00 | PTP4A3 (0.60) | PTP4A3NAT1GSK3APIM1PIM2 | |
| SCHEMBL8177375 | 0.86 | PTP4A3 (0.77) | PTP4A3NAT1GSK3APIM1PIM2 | |
| SCHEMBL8187546 | 0.86 | PTP4A3 (0.57) | PTP4A3NAT1GSK3APDE4BMEN1 | |
| SCHEMBL8181082 | 0.85 | IGF1R (0.61) | PTP4A3GSK3APIM1PIM2TTR | |
| SCHEMBL1249948 | 0.84 | NAT1 (0.74) | NAT1GSK3APIM1PIM2TTR | |
| SCHEMBL1249945 | 0.84 | NAT1 (0.74) | NAT1GSK3APIM1PIM2TTR | |
| SCHEMBL30990563 | 0.84 | NAT1 (0.74) | NAT1GSK3APIM1PIM2TTR | |
| SCHEMBL8183772 | 0.81 | PIM1 (0.48) | PTP4A3GSK3APIM1PIM2TTR | |
| SCHEMBL8182980 | 0.81 | PIM1 (0.51) | PTP4A3NAT1PIM1TTRPIK3CG | |
| SCHEMBL8182982 | 0.81 | PIM1 (0.51) | PTP4A3NAT1PIM1TTRPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| US-20060258561-A1 | Novel NPH insulin preparations | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | US | disclosed |
| WO-2006082245-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING INSULIN, ZINC IONS AND A ZINC-BINDING LIGAND | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | NOVO NORDISK A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| EP-1610812-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2006-01-04 | — | — | EP | disclosed |
| EP-1585541-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2005-10-19 | — | — | EP | disclosed |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | NOVO NORDISK A/S (DK) | 2005-03-24 | — | — | US | disclosed |
| WO-2004080480-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004056347-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| WO-2000018746-A1 | THIAZOLIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258561-A1 | Novel NPH insulin preparations | IAPP, HBB, INSR | PTP4A3 1682/4885NAT1 2886/4885GSK3A 3980/4885 |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | IAPP, GPR119, INSR | PTP4A3 3124/4885NAT1 4021/4885GSK3A 4521/4885 |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | IAPP, IRS1, INSR | PTP4A3 2671/4885NAT1 4479/4885GSK3A 3934/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | PTP4A3 1732/4885NAT1 4542/4885GSK3A 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.